UPDATE: Bank of America Upgrades Mindray Medical International to Buy; Selloff Creates Opportunity

Bank of America raised its rating on Mindray Medical International MR from Neutral to Buy and increased its price objective from $35 to $36. Bank of America noted, "MR share were sharply down (-8%) in the last trading session due to resurfaced concerns on US business slow down and NA management uncertainty. We upgrade MR to Buy and raise our PO to US$36 as (1) we believe the selloff is overdone and offers buying opportunity as the shares become attractively valued at 15x 2013PE; (2) we believe MR should be able to reaffirm its 2012 guidance and offer benign 2013 forecast next week at a global healthcare conference which could provide support to the share price; (3) Mindray is fundamentally a solid leader in the medical equipment sector with relatively low policy risk as compared with its peers in the China healthcare sector." Mindray Medical International closed at $30.17 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesPre-Market OutlookAnalyst RatingsBank of America
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!